The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

Streeting has also promised to reduce the time it takes to get clinical trials approved by cutting red tape, pointing out ...